Severity: Warning
Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 197
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 197
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 271
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1075
Function: getPubMedXML
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3195
Function: GetPubMedArticleOutput_2016
File: /var/www/html/application/controllers/Detail.php
Line: 597
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 511
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 317
Function: require_once
98%
921
2 minutes
20
This is an English-translated version of the Japanese Dermatological Association's clinical practice guidelines for alopecia areata (AA) 2024. It includes the sections of summary, pathogenesis and epidemiology, evaluation and diagnosis, and treatment of AA. Updates based on recent evidence/advances were made in each part. The treatment part contains the statements of recommendation for 25 clinical questions (CQs) with respective recommendation/evidence levels. AA-cube, a graphic illustration conceptualizing the treatment strategy based on individual patients' factors, was newly proposed. Taking into account the recent approval of a JAK inhibitor and a JAK3/TEC family kinase selective inhibitor, a CQ for these modalities was also added. These guidelines aim to support evidence-based management of AA as well as prompt understanding of disease etiopathogenesis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/1346-8138.17859 | DOI Listing |